Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of diabetes and pre-diabetes

HK40137410APending Publication Date: 2026-09-11OVID THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026125146
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-02-17
Filing Date
2026-06-23
Publication Date
2026-09-11
Patent Text Reader

Abstract

Methods and compositions for treating diabetes or prediabetes include administering (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof to a subject diagnosed with diabetes or prediabetes. In embodiments, administering (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof to a subject diagnosed with diabetes or prediabetes is effective to lower one or more of HbA1c level, fasting plasma glucose level, 2-hour oral glucose tolerance test (OGTT) result level, and random plasma glucose level. (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof may optionally be administered in combination with a hypoglycemic agent.
Need to check novelty before this filing date? Find Prior Art

Description

Methods and compositions for treating diabetes or prediabetes include administering (S)-3-amino-4-(difluoromethylene)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof to a subject diagnosed with diabetes or prediabetes. In embodiments, administration of (S)-3-amino-4-(difluoromethylene)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof to a subject diagnosed with diabetes or prediabetes effectively reduces one or more of HbA1c levels, fasting plasma glucose levels, 2-hour oral glucose tolerance test (OGTT) results, and random plasma glucose levels. (S)-3-amino-4-(difluoromethylene)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof may optionally be administered in combination with a hypoglycemic agent. Abstract

Claims

What is claimed is:

1. A method of treating diabetes comprising administering an effective amount of (S)-3-amino-4- (difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof to a subject in need thereof. 2 The method of treating diabetes according to claim 1, wherein the diabetes is type 2 diabetes. 3 The method of treating diabetes according to claim 1, wherein the diabetes is type 1 diabetes. 4 The method of treating diabetes according to claim 1, wherein the (S)-3-amino-4- (difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof in an amount effective to lower one or more of HbA1c level, fasting plasma glucose level, 2-hour oral glucose tolerance test (OGTT) result level, and random plasma glucose level. 5 The method of treating diabetes according to claim 4, wherein the HbA1c level is lowered by an amount greater than 0.5%. 6 The method of treating diabetes according to claim 4, wherein the HbA1c level is lowered by an amount greater than 1.0%. 7 The method of treating diabetes according to claim 1, wherein the (S)-3-amino-4- (difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof is administered in an amount ranging from about 0.01 mg to about 750 mg. 8 The method of treating diabetes according to claim 1, wherein the (S)-3-amino-4- (difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof is administered in combination with one or more hypoglycemic agents selected from the group consisting of a biguanide, a dipeptidyl peptidase-4 (DPP-4) inhibitor, a sulphonylurea, a thiazolidinedione, a glinide, an alpha-glucosidase blocker, an glucagon-like peptide-1 receptor agonist, insulin and an insulin analog.

9. A method of treating prediabetes comprising administering an effective amount of (S)-3-amino- 4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof to a subject in need thereof.

10. The method of treating prediabetes according to claim 9, wherein the (S)-3-amino-4- (difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof is administered to a subject in need thereof in an amount effective to lower one or more of HbA1c level, fasting plasma glucose level, 2-hour oral glucose tolerance test (OGTT) result level, and random plasma glucose level.

11. The method of treating prediabetes according to claim 10, wherein the HbA1c level is lowered by an amount greater than 0.5%.

12. The method of treating prediabetes according to claim 10, wherein the HbA1c level is lowered by an amount greater than 1.0%.

13. The method of treating prediabetes according to claim 9, wherein the (S)-3-amino-4- (difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof is administered in an amount ranging from about 0.01 mg to about 750 mg.

14. The method of treating prediabetes according to claim 9, wherein the (S)-3-amino-4- (difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof is administered in combination with one or more hypoglycemic agents selected from the group consisting of a biguanide, a dipeptidyl peptidase-4 (DPP-4) inhibitor, a sulphonylurea, a thiazolidinedione, a glinide, an alpha-glucosidase blocker, an glucagon-like peptide-1 receptor agonist, insulin and an insulin analog.

15. A method of treating diabetes and sleep apnea comprising administering (S)-3-amino-4- (difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof to a subject diagnosed with the diabetes and sleep apnea in an amount effective to reduce episodes of sleep apnea.

16. The method of treating diabetes and sleep apnea according to claim 15, wherein the diabetes disease is type 2 diabetes.

17. The method of treating diabetes and sleep apnea according to claim 15, wherein the diabetes is type I diabetes.

18. The method of treating diabetes and sleep apnea according to claim 15, wherein the (S)-3-amino- 4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof is administered in an amount ranging from about 0.01 mg to about 750 mg.

19. The method of treating diabetes and sleep apnea according to claim 15, wherein the (S)-3-amino- 4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid or a pharmaceutically acceptable salt thereof is administered in combination with one or more hypoglycemic agents selected from the group consisting of a biguanide, a dipeptidyl peptidase-4 (DPP-4) inhibitor, a sulphonylurea, a thiazolidinedione, a glinide, an alpha-glucosidase blocker, an glucagon-like peptide-1 receptor agonist, insulin and an insulin analog.

20. The method of treating diabetes and sleep apnea according to claim 15, wherein the administering is effective to lower one or more of HbA1c level, fasting plasma glucose level, 2- hour oral glucose tolerance test (OGTT) result level, and random plasma glucose level in the subject.

21. The method of treating diabetes and sleep apnea according to claim 20, wherein the HbA1c level is lowered by an amount greater than 0.5%.

22. The method of treating diabetes and sleep apnea according to claim 20, wherein the HbA1c level is lowered by an amount greater than 1%.